Global Wet Age Related Macular Degeneration (AMD) Market 2023 by Company, Regions, Type and Application, Forecast to 2029

Page: 100

Published Date: 07 Jan 2023

Category: Medical Care

PDF Download

Get FREE Sample

Customize Request

Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags

Description

Increased disease burden due to rising geriatric population is one of the major factors driving the growth of the global age-related macular degeneration (AMD) market. This market is expected to surpass a valuation of USD 2,200 Mn by the end of 2023. AMD remains a major cause of central visual loss, effecting close to 10% of people older than 65 years and over 25% of people older than 75 years globally.

According to our (Global Info Research) latest study, the global Wet Age Related Macular Degeneration (AMD) market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

Increased awareness among people about the condition has influenced the AMD treatment global demand. At the same time, the arrival of off-patent blockbuster drugs is reflecting favorably on the market particularly in third-world countries. This has allowed small-scale drug manufactures to penetrate untapped markets.

This report is a detailed and comprehensive analysis for global Wet Age Related Macular Degeneration (AMD) market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Age. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.

Key Features:
Global Wet Age Related Macular Degeneration (AMD) market size and forecasts, in consumption value ($ Million), 2018-2029
Global Wet Age Related Macular Degeneration (AMD) market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global Wet Age Related Macular Degeneration (AMD) market size and forecasts, by Type and by Age, in consumption value ($ Million), 2018-2029
Global Wet Age Related Macular Degeneration (AMD) market shares of main players, in revenue ($ Million), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Wet Age Related Macular Degeneration (AMD)
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Wet Age Related Macular Degeneration (AMD) market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novartis International (Switzerland), Bayer (Germany), Acucela (US), Neurotech Pharmaceuticals (US) and Ophthotech (US), etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Market segmentation
Wet Age Related Macular Degeneration (AMD) market is split by Type and by Age. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Age. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
    Wet Age-Related Macular Degeneration (Wet AMD)
    Dry Age-Related Macular Degeneration (Dry AMD)

Market segment by Age
    Above 75 Years
    Above 60 Years
    Above 40 Years

Market segment by players, this report covers
    Novartis International (Switzerland)
    Bayer (Germany)
    Acucela (US)
    Neurotech Pharmaceuticals (US)
    Ophthotech (US)
    GlaxoSmithKline (US)
    Alimera Sciences (US)
    StemCell (Canada)
    F. Hoffmann-La Roche (Switzerland)
    Regeneron Pharmaceutical (US)
    Allergan (Ireland)
    Adverum Biotechnologies (US)
    Gilead Sciences (US)

Market segment by regions, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
    South America (Brazil, Argentina and Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Wet Age Related Macular Degeneration (AMD) product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Wet Age Related Macular Degeneration (AMD), with revenue, gross margin and global market share of Wet Age Related Macular Degeneration (AMD) from 2018 to 2023.
Chapter 3, the Wet Age Related Macular Degeneration (AMD) competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Wet Age Related Macular Degeneration (AMD) market forecast, by regions, type and age, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Wet Age Related Macular Degeneration (AMD).
Chapter 13, to describe Wet Age Related Macular Degeneration (AMD) research findings and conclusion.

Table of Contents

1 Market Overview
    1.1 Product Overview and Scope of Wet Age Related Macular Degeneration (AMD)
    1.2 Market Estimation Caveats and Base Year
    1.3 Classification of Wet Age Related Macular Degeneration (AMD) by Type
        1.3.1 Overview: Global Wet Age Related Macular Degeneration (AMD) Market Size by Type: 2018 Versus 2022 Versus 2029
        1.3.2 Global Wet Age Related Macular Degeneration (AMD) Consumption Value Market Share by Type in 2022
        1.3.3 Wet Age-Related Macular Degeneration (Wet AMD)
        1.3.4 Dry Age-Related Macular Degeneration (Dry AMD)
    1.4 Global Wet Age Related Macular Degeneration (AMD) Market by Age
        1.4.1 Overview: Global Wet Age Related Macular Degeneration (AMD) Market Size by Age: 2018 Versus 2022 Versus 2029
        1.4.2 Above 75 Years
        1.4.3 Above 60 Years
        1.4.4 Above 40 Years
    1.5 Global Wet Age Related Macular Degeneration (AMD) Market Size & Forecast
    1.6 Global Wet Age Related Macular Degeneration (AMD) Market Size and Forecast by Region
        1.6.1 Global Wet Age Related Macular Degeneration (AMD) Market Size by Region: 2018 VS 2022 VS 2029
        1.6.2 Global Wet Age Related Macular Degeneration (AMD) Market Size by Region, (2018-2029)
        1.6.3 North America Wet Age Related Macular Degeneration (AMD) Market Size and Prospect (2018-2029)
        1.6.4 Europe Wet Age Related Macular Degeneration (AMD) Market Size and Prospect (2018-2029)
        1.6.5 Asia-Pacific Wet Age Related Macular Degeneration (AMD) Market Size and Prospect (2018-2029)
        1.6.6 South America Wet Age Related Macular Degeneration (AMD) Market Size and Prospect (2018-2029)
        1.6.7 Middle East and Africa Wet Age Related Macular Degeneration (AMD) Market Size and Prospect (2018-2029)

2 Company Profiles
    2.1 Novartis International (Switzerland)
        2.1.1 Novartis International (Switzerland) Details
        2.1.2 Novartis International (Switzerland) Major Business
        2.1.3 Novartis International (Switzerland) Wet Age Related Macular Degeneration (AMD) Product and Solutions
        2.1.4 Novartis International (Switzerland) Wet Age Related Macular Degeneration (AMD) Revenue, Gross Margin and Market Share (2018-2023)
        2.1.5 Novartis International (Switzerland) Recent Developments and Future Plans
    2.2 Bayer (Germany)
        2.2.1 Bayer (Germany) Details
        2.2.2 Bayer (Germany) Major Business
        2.2.3 Bayer (Germany) Wet Age Related Macular Degeneration (AMD) Product and Solutions
        2.2.4 Bayer (Germany) Wet Age Related Macular Degeneration (AMD) Revenue, Gross Margin and Market Share (2018-2023)
        2.2.5 Bayer (Germany) Recent Developments and Future Plans
    2.3 Acucela (US)
        2.3.1 Acucela (US) Details
        2.3.2 Acucela (US) Major Business
        2.3.3 Acucela (US) Wet Age Related Macular Degeneration (AMD) Product and Solutions
        2.3.4 Acucela (US) Wet Age Related Macular Degeneration (AMD) Revenue, Gross Margin and Market Share (2018-2023)
        2.3.5 Acucela (US) Recent Developments and Future Plans
    2.4 Neurotech Pharmaceuticals (US)
        2.4.1 Neurotech Pharmaceuticals (US) Details
        2.4.2 Neurotech Pharmaceuticals (US) Major Business
        2.4.3 Neurotech Pharmaceuticals (US) Wet Age Related Macular Degeneration (AMD) Product and Solutions
        2.4.4 Neurotech Pharmaceuticals (US) Wet Age Related Macular Degeneration (AMD) Revenue, Gross Margin and Market Share (2018-2023)
        2.4.5 Neurotech Pharmaceuticals (US) Recent Developments and Future Plans
    2.5 Ophthotech (US)
        2.5.1 Ophthotech (US) Details
        2.5.2 Ophthotech (US) Major Business
        2.5.3 Ophthotech (US) Wet Age Related Macular Degeneration (AMD) Product and Solutions
        2.5.4 Ophthotech (US) Wet Age Related Macular Degeneration (AMD) Revenue, Gross Margin and Market Share (2018-2023)
        2.5.5 Ophthotech (US) Recent Developments and Future Plans
    2.6 GlaxoSmithKline (US)
        2.6.1 GlaxoSmithKline (US) Details
        2.6.2 GlaxoSmithKline (US) Major Business
        2.6.3 GlaxoSmithKline (US) Wet Age Related Macular Degeneration (AMD) Product and Solutions
        2.6.4 GlaxoSmithKline (US) Wet Age Related Macular Degeneration (AMD) Revenue, Gross Margin and Market Share (2018-2023)
        2.6.5 GlaxoSmithKline (US) Recent Developments and Future Plans
    2.7 Alimera Sciences (US)
        2.7.1 Alimera Sciences (US) Details
        2.7.2 Alimera Sciences (US) Major Business
        2.7.3 Alimera Sciences (US) Wet Age Related Macular Degeneration (AMD) Product and Solutions
        2.7.4 Alimera Sciences (US) Wet Age Related Macular Degeneration (AMD) Revenue, Gross Margin and Market Share (2018-2023)
        2.7.5 Alimera Sciences (US) Recent Developments and Future Plans
    2.8 StemCell (Canada)
        2.8.1 StemCell (Canada) Details
        2.8.2 StemCell (Canada) Major Business
        2.8.3 StemCell (Canada) Wet Age Related Macular Degeneration (AMD) Product and Solutions
        2.8.4 StemCell (Canada) Wet Age Related Macular Degeneration (AMD) Revenue, Gross Margin and Market Share (2018-2023)
        2.8.5 StemCell (Canada) Recent Developments and Future Plans
    2.9 F. Hoffmann-La Roche (Switzerland)
        2.9.1 F. Hoffmann-La Roche (Switzerland) Details
        2.9.2 F. Hoffmann-La Roche (Switzerland) Major Business
        2.9.3 F. Hoffmann-La Roche (Switzerland) Wet Age Related Macular Degeneration (AMD) Product and Solutions
        2.9.4 F. Hoffmann-La Roche (Switzerland) Wet Age Related Macular Degeneration (AMD) Revenue, Gross Margin and Market Share (2018-2023)
        2.9.5 F. Hoffmann-La Roche (Switzerland) Recent Developments and Future Plans
    2.10 Regeneron Pharmaceutical (US)
        2.10.1 Regeneron Pharmaceutical (US) Details
        2.10.2 Regeneron Pharmaceutical (US) Major Business
        2.10.3 Regeneron Pharmaceutical (US) Wet Age Related Macular Degeneration (AMD) Product and Solutions
        2.10.4 Regeneron Pharmaceutical (US) Wet Age Related Macular Degeneration (AMD) Revenue, Gross Margin and Market Share (2018-2023)
        2.10.5 Regeneron Pharmaceutical (US) Recent Developments and Future Plans
    2.11 Allergan (Ireland)
        2.11.1 Allergan (Ireland) Details
        2.11.2 Allergan (Ireland) Major Business
        2.11.3 Allergan (Ireland) Wet Age Related Macular Degeneration (AMD) Product and Solutions
        2.11.4 Allergan (Ireland) Wet Age Related Macular Degeneration (AMD) Revenue, Gross Margin and Market Share (2018-2023)
        2.11.5 Allergan (Ireland) Recent Developments and Future Plans
    2.12 Adverum Biotechnologies (US)
        2.12.1 Adverum Biotechnologies (US) Details
        2.12.2 Adverum Biotechnologies (US) Major Business
        2.12.3 Adverum Biotechnologies (US) Wet Age Related Macular Degeneration (AMD) Product and Solutions
        2.12.4 Adverum Biotechnologies (US) Wet Age Related Macular Degeneration (AMD) Revenue, Gross Margin and Market Share (2018-2023)
        2.12.5 Adverum Biotechnologies (US) Recent Developments and Future Plans
    2.13 Gilead Sciences (US)
        2.13.1 Gilead Sciences (US) Details
        2.13.2 Gilead Sciences (US) Major Business
        2.13.3 Gilead Sciences (US) Wet Age Related Macular Degeneration (AMD) Product and Solutions
        2.13.4 Gilead Sciences (US) Wet Age Related Macular Degeneration (AMD) Revenue, Gross Margin and Market Share (2018-2023)
        2.13.5 Gilead Sciences (US) Recent Developments and Future Plans

3 Market Competition, by Players
    3.1 Global Wet Age Related Macular Degeneration (AMD) Revenue and Share by Players (2018-2023)
    3.2 Market Share Analysis (2022)
        3.2.1 Market Share of Wet Age Related Macular Degeneration (AMD) by Company Revenue
        3.2.2 Top 3 Wet Age Related Macular Degeneration (AMD) Players Market Share in 2022
        3.2.3 Top 6 Wet Age Related Macular Degeneration (AMD) Players Market Share in 2022
    3.3 Wet Age Related Macular Degeneration (AMD) Market: Overall Company Footprint Analysis
        3.3.1 Wet Age Related Macular Degeneration (AMD) Market: Region Footprint
        3.3.2 Wet Age Related Macular Degeneration (AMD) Market: Company Product Type Footprint
        3.3.3 Wet Age Related Macular Degeneration (AMD) Market: Company Product Application Footprint
    3.4 New Market Entrants and Barriers to Market Entry
    3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type
    4.1 Global Wet Age Related Macular Degeneration (AMD) Consumption Value and Market Share by Type (2018-2023)
    4.2 Global Wet Age Related Macular Degeneration (AMD) Market Forecast by Type (2024-2029)

5 Market Size Segment by Age
    5.1 Global Wet Age Related Macular Degeneration (AMD) Consumption Value Market Share by Age (2018-2023)
    5.2 Global Wet Age Related Macular Degeneration (AMD) Market Forecast by Age (2024-2029)

6 North America
    6.1 North America Wet Age Related Macular Degeneration (AMD) Consumption Value by Type (2018-2029)
    6.2 North America Wet Age Related Macular Degeneration (AMD) Consumption Value by Age (2018-2029)
    6.3 North America Wet Age Related Macular Degeneration (AMD) Market Size by Country
        6.3.1 North America Wet Age Related Macular Degeneration (AMD) Consumption Value by Country (2018-2029)
        6.3.2 United States Wet Age Related Macular Degeneration (AMD) Market Size and Forecast (2018-2029)
        6.3.3 Canada Wet Age Related Macular Degeneration (AMD) Market Size and Forecast (2018-2029)
        6.3.4 Mexico Wet Age Related Macular Degeneration (AMD) Market Size and Forecast (2018-2029)

7 Europe
    7.1 Europe Wet Age Related Macular Degeneration (AMD) Consumption Value by Type (2018-2029)
    7.2 Europe Wet Age Related Macular Degeneration (AMD) Consumption Value by Age (2018-2029)
    7.3 Europe Wet Age Related Macular Degeneration (AMD) Market Size by Country
        7.3.1 Europe Wet Age Related Macular Degeneration (AMD) Consumption Value by Country (2018-2029)
        7.3.2 Germany Wet Age Related Macular Degeneration (AMD) Market Size and Forecast (2018-2029)
        7.3.3 France Wet Age Related Macular Degeneration (AMD) Market Size and Forecast (2018-2029)
        7.3.4 United Kingdom Wet Age Related Macular Degeneration (AMD) Market Size and Forecast (2018-2029)
        7.3.5 Russia Wet Age Related Macular Degeneration (AMD) Market Size and Forecast (2018-2029)
        7.3.6 Italy Wet Age Related Macular Degeneration (AMD) Market Size and Forecast (2018-2029)

8 Asia-Pacific
    8.1 Asia-Pacific Wet Age Related Macular Degeneration (AMD) Consumption Value by Type (2018-2029)
    8.2 Asia-Pacific Wet Age Related Macular Degeneration (AMD) Consumption Value by Age (2018-2029)
    8.3 Asia-Pacific Wet Age Related Macular Degeneration (AMD) Market Size by Region
        8.3.1 Asia-Pacific Wet Age Related Macular Degeneration (AMD) Consumption Value by Region (2018-2029)
        8.3.2 China Wet Age Related Macular Degeneration (AMD) Market Size and Forecast (2018-2029)
        8.3.3 Japan Wet Age Related Macular Degeneration (AMD) Market Size and Forecast (2018-2029)
        8.3.4 South Korea Wet Age Related Macular Degeneration (AMD) Market Size and Forecast (2018-2029)
        8.3.5 India Wet Age Related Macular Degeneration (AMD) Market Size and Forecast (2018-2029)
        8.3.6 Southeast Asia Wet Age Related Macular Degeneration (AMD) Market Size and Forecast (2018-2029)
        8.3.7 Australia Wet Age Related Macular Degeneration (AMD) Market Size and Forecast (2018-2029)

9 South America
    9.1 South America Wet Age Related Macular Degeneration (AMD) Consumption Value by Type (2018-2029)
    9.2 South America Wet Age Related Macular Degeneration (AMD) Consumption Value by Age (2018-2029)
    9.3 South America Wet Age Related Macular Degeneration (AMD) Market Size by Country
        9.3.1 South America Wet Age Related Macular Degeneration (AMD) Consumption Value by Country (2018-2029)
        9.3.2 Brazil Wet Age Related Macular Degeneration (AMD) Market Size and Forecast (2018-2029)
        9.3.3 Argentina Wet Age Related Macular Degeneration (AMD) Market Size and Forecast (2018-2029)

10 Middle East & Africa
    10.1 Middle East & Africa Wet Age Related Macular Degeneration (AMD) Consumption Value by Type (2018-2029)
    10.2 Middle East & Africa Wet Age Related Macular Degeneration (AMD) Consumption Value by Age (2018-2029)
    10.3 Middle East & Africa Wet Age Related Macular Degeneration (AMD) Market Size by Country
        10.3.1 Middle East & Africa Wet Age Related Macular Degeneration (AMD) Consumption Value by Country (2018-2029)
        10.3.2 Turkey Wet Age Related Macular Degeneration (AMD) Market Size and Forecast (2018-2029)
        10.3.3 Saudi Arabia Wet Age Related Macular Degeneration (AMD) Market Size and Forecast (2018-2029)
        10.3.4 UAE Wet Age Related Macular Degeneration (AMD) Market Size and Forecast (2018-2029)

11 Market Dynamics
    11.1 Wet Age Related Macular Degeneration (AMD) Market Drivers
    11.2 Wet Age Related Macular Degeneration (AMD) Market Restraints
    11.3 Wet Age Related Macular Degeneration (AMD) Trends Analysis
    11.4 Porters Five Forces Analysis
        11.4.1 Threat of New Entrants
        11.4.2 Bargaining Power of Suppliers
        11.4.3 Bargaining Power of Buyers
        11.4.4 Threat of Substitutes
        11.4.5 Competitive Rivalry
    11.5 Influence of COVID-19 and Russia-Ukraine War
        11.5.1 Influence of COVID-19
        11.5.2 Influence of Russia-Ukraine War

12 Industry Chain Analysis
    12.1 Wet Age Related Macular Degeneration (AMD) Industry Chain
    12.2 Wet Age Related Macular Degeneration (AMD) Upstream Analysis
    12.3 Wet Age Related Macular Degeneration (AMD) Midstream Analysis
    12.4 Wet Age Related Macular Degeneration (AMD) Downstream Analysis

13 Research Findings and Conclusion

14 Appendix
    14.1 Methodology
    14.2 Research Process and Data Source
    14.3 Disclaimer

Table of Figures

List of Tables
    Table 1. Global Wet Age Related Macular Degeneration (AMD) Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
    Table 2. Global Wet Age Related Macular Degeneration (AMD) Consumption Value by Age, (USD Million), 2018 & 2022 & 2029
    Table 3. Global Wet Age Related Macular Degeneration (AMD) Consumption Value by Region (2018-2023) & (USD Million)
    Table 4. Global Wet Age Related Macular Degeneration (AMD) Consumption Value by Region (2024-2029) & (USD Million)
    Table 5. Novartis International (Switzerland) Company Information, Head Office, and Major Competitors
    Table 6. Novartis International (Switzerland) Major Business
    Table 7. Novartis International (Switzerland) Wet Age Related Macular Degeneration (AMD) Product and Solutions
    Table 8. Novartis International (Switzerland) Wet Age Related Macular Degeneration (AMD) Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 9. Novartis International (Switzerland) Recent Developments and Future Plans
    Table 10. Bayer (Germany) Company Information, Head Office, and Major Competitors
    Table 11. Bayer (Germany) Major Business
    Table 12. Bayer (Germany) Wet Age Related Macular Degeneration (AMD) Product and Solutions
    Table 13. Bayer (Germany) Wet Age Related Macular Degeneration (AMD) Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 14. Bayer (Germany) Recent Developments and Future Plans
    Table 15. Acucela (US) Company Information, Head Office, and Major Competitors
    Table 16. Acucela (US) Major Business
    Table 17. Acucela (US) Wet Age Related Macular Degeneration (AMD) Product and Solutions
    Table 18. Acucela (US) Wet Age Related Macular Degeneration (AMD) Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 19. Acucela (US) Recent Developments and Future Plans
    Table 20. Neurotech Pharmaceuticals (US) Company Information, Head Office, and Major Competitors
    Table 21. Neurotech Pharmaceuticals (US) Major Business
    Table 22. Neurotech Pharmaceuticals (US) Wet Age Related Macular Degeneration (AMD) Product and Solutions
    Table 23. Neurotech Pharmaceuticals (US) Wet Age Related Macular Degeneration (AMD) Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 24. Neurotech Pharmaceuticals (US) Recent Developments and Future Plans
    Table 25. Ophthotech (US) Company Information, Head Office, and Major Competitors
    Table 26. Ophthotech (US) Major Business
    Table 27. Ophthotech (US) Wet Age Related Macular Degeneration (AMD) Product and Solutions
    Table 28. Ophthotech (US) Wet Age Related Macular Degeneration (AMD) Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 29. Ophthotech (US) Recent Developments and Future Plans
    Table 30. GlaxoSmithKline (US) Company Information, Head Office, and Major Competitors
    Table 31. GlaxoSmithKline (US) Major Business
    Table 32. GlaxoSmithKline (US) Wet Age Related Macular Degeneration (AMD) Product and Solutions
    Table 33. GlaxoSmithKline (US) Wet Age Related Macular Degeneration (AMD) Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 34. GlaxoSmithKline (US) Recent Developments and Future Plans
    Table 35. Alimera Sciences (US) Company Information, Head Office, and Major Competitors
    Table 36. Alimera Sciences (US) Major Business
    Table 37. Alimera Sciences (US) Wet Age Related Macular Degeneration (AMD) Product and Solutions
    Table 38. Alimera Sciences (US) Wet Age Related Macular Degeneration (AMD) Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 39. Alimera Sciences (US) Recent Developments and Future Plans
    Table 40. StemCell (Canada) Company Information, Head Office, and Major Competitors
    Table 41. StemCell (Canada) Major Business
    Table 42. StemCell (Canada) Wet Age Related Macular Degeneration (AMD) Product and Solutions
    Table 43. StemCell (Canada) Wet Age Related Macular Degeneration (AMD) Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 44. StemCell (Canada) Recent Developments and Future Plans
    Table 45. F. Hoffmann-La Roche (Switzerland) Company Information, Head Office, and Major Competitors
    Table 46. F. Hoffmann-La Roche (Switzerland) Major Business
    Table 47. F. Hoffmann-La Roche (Switzerland) Wet Age Related Macular Degeneration (AMD) Product and Solutions
    Table 48. F. Hoffmann-La Roche (Switzerland) Wet Age Related Macular Degeneration (AMD) Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 49. F. Hoffmann-La Roche (Switzerland) Recent Developments and Future Plans
    Table 50. Regeneron Pharmaceutical (US) Company Information, Head Office, and Major Competitors
    Table 51. Regeneron Pharmaceutical (US) Major Business
    Table 52. Regeneron Pharmaceutical (US) Wet Age Related Macular Degeneration (AMD) Product and Solutions
    Table 53. Regeneron Pharmaceutical (US) Wet Age Related Macular Degeneration (AMD) Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 54. Regeneron Pharmaceutical (US) Recent Developments and Future Plans
    Table 55. Allergan (Ireland) Company Information, Head Office, and Major Competitors
    Table 56. Allergan (Ireland) Major Business
    Table 57. Allergan (Ireland) Wet Age Related Macular Degeneration (AMD) Product and Solutions
    Table 58. Allergan (Ireland) Wet Age Related Macular Degeneration (AMD) Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 59. Allergan (Ireland) Recent Developments and Future Plans
    Table 60. Adverum Biotechnologies (US) Company Information, Head Office, and Major Competitors
    Table 61. Adverum Biotechnologies (US) Major Business
    Table 62. Adverum Biotechnologies (US) Wet Age Related Macular Degeneration (AMD) Product and Solutions
    Table 63. Adverum Biotechnologies (US) Wet Age Related Macular Degeneration (AMD) Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 64. Adverum Biotechnologies (US) Recent Developments and Future Plans
    Table 65. Gilead Sciences (US) Company Information, Head Office, and Major Competitors
    Table 66. Gilead Sciences (US) Major Business
    Table 67. Gilead Sciences (US) Wet Age Related Macular Degeneration (AMD) Product and Solutions
    Table 68. Gilead Sciences (US) Wet Age Related Macular Degeneration (AMD) Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 69. Gilead Sciences (US) Recent Developments and Future Plans
    Table 70. Global Wet Age Related Macular Degeneration (AMD) Revenue (USD Million) by Players (2018-2023)
    Table 71. Global Wet Age Related Macular Degeneration (AMD) Revenue Share by Players (2018-2023)
    Table 72. Breakdown of Wet Age Related Macular Degeneration (AMD) by Company Type (Tier 1, Tier 2, and Tier 3)
    Table 73. Market Position of Players in Wet Age Related Macular Degeneration (AMD), (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
    Table 74. Head Office of Key Wet Age Related Macular Degeneration (AMD) Players
    Table 75. Wet Age Related Macular Degeneration (AMD) Market: Company Product Type Footprint
    Table 76. Wet Age Related Macular Degeneration (AMD) Market: Company Product Application Footprint
    Table 77. Wet Age Related Macular Degeneration (AMD) New Market Entrants and Barriers to Market Entry
    Table 78. Wet Age Related Macular Degeneration (AMD) Mergers, Acquisition, Agreements, and Collaborations
    Table 79. Global Wet Age Related Macular Degeneration (AMD) Consumption Value (USD Million) by Type (2018-2023)
    Table 80. Global Wet Age Related Macular Degeneration (AMD) Consumption Value Share by Type (2018-2023)
    Table 81. Global Wet Age Related Macular Degeneration (AMD) Consumption Value Forecast by Type (2024-2029)
    Table 82. Global Wet Age Related Macular Degeneration (AMD) Consumption Value by Age (2018-2023)
    Table 83. Global Wet Age Related Macular Degeneration (AMD) Consumption Value Forecast by Age (2024-2029)
    Table 84. North America Wet Age Related Macular Degeneration (AMD) Consumption Value by Type (2018-2023) & (USD Million)
    Table 85. North America Wet Age Related Macular Degeneration (AMD) Consumption Value by Type (2024-2029) & (USD Million)
    Table 86. North America Wet Age Related Macular Degeneration (AMD) Consumption Value by Age (2018-2023) & (USD Million)
    Table 87. North America Wet Age Related Macular Degeneration (AMD) Consumption Value by Age (2024-2029) & (USD Million)
    Table 88. North America Wet Age Related Macular Degeneration (AMD) Consumption Value by Country (2018-2023) & (USD Million)
    Table 89. North America Wet Age Related Macular Degeneration (AMD) Consumption Value by Country (2024-2029) & (USD Million)
    Table 90. Europe Wet Age Related Macular Degeneration (AMD) Consumption Value by Type (2018-2023) & (USD Million)
    Table 91. Europe Wet Age Related Macular Degeneration (AMD) Consumption Value by Type (2024-2029) & (USD Million)
    Table 92. Europe Wet Age Related Macular Degeneration (AMD) Consumption Value by Age (2018-2023) & (USD Million)
    Table 93. Europe Wet Age Related Macular Degeneration (AMD) Consumption Value by Age (2024-2029) & (USD Million)
    Table 94. Europe Wet Age Related Macular Degeneration (AMD) Consumption Value by Country (2018-2023) & (USD Million)
    Table 95. Europe Wet Age Related Macular Degeneration (AMD) Consumption Value by Country (2024-2029) & (USD Million)
    Table 96. Asia-Pacific Wet Age Related Macular Degeneration (AMD) Consumption Value by Type (2018-2023) & (USD Million)
    Table 97. Asia-Pacific Wet Age Related Macular Degeneration (AMD) Consumption Value by Type (2024-2029) & (USD Million)
    Table 98. Asia-Pacific Wet Age Related Macular Degeneration (AMD) Consumption Value by Age (2018-2023) & (USD Million)
    Table 99. Asia-Pacific Wet Age Related Macular Degeneration (AMD) Consumption Value by Age (2024-2029) & (USD Million)
    Table 100. Asia-Pacific Wet Age Related Macular Degeneration (AMD) Consumption Value by Region (2018-2023) & (USD Million)
    Table 101. Asia-Pacific Wet Age Related Macular Degeneration (AMD) Consumption Value by Region (2024-2029) & (USD Million)
    Table 102. South America Wet Age Related Macular Degeneration (AMD) Consumption Value by Type (2018-2023) & (USD Million)
    Table 103. South America Wet Age Related Macular Degeneration (AMD) Consumption Value by Type (2024-2029) & (USD Million)
    Table 104. South America Wet Age Related Macular Degeneration (AMD) Consumption Value by Age (2018-2023) & (USD Million)
    Table 105. South America Wet Age Related Macular Degeneration (AMD) Consumption Value by Age (2024-2029) & (USD Million)
    Table 106. South America Wet Age Related Macular Degeneration (AMD) Consumption Value by Country (2018-2023) & (USD Million)
    Table 107. South America Wet Age Related Macular Degeneration (AMD) Consumption Value by Country (2024-2029) & (USD Million)
    Table 108. Middle East & Africa Wet Age Related Macular Degeneration (AMD) Consumption Value by Type (2018-2023) & (USD Million)
    Table 109. Middle East & Africa Wet Age Related Macular Degeneration (AMD) Consumption Value by Type (2024-2029) & (USD Million)
    Table 110. Middle East & Africa Wet Age Related Macular Degeneration (AMD) Consumption Value by Age (2018-2023) & (USD Million)
    Table 111. Middle East & Africa Wet Age Related Macular Degeneration (AMD) Consumption Value by Age (2024-2029) & (USD Million)
    Table 112. Middle East & Africa Wet Age Related Macular Degeneration (AMD) Consumption Value by Country (2018-2023) & (USD Million)
    Table 113. Middle East & Africa Wet Age Related Macular Degeneration (AMD) Consumption Value by Country (2024-2029) & (USD Million)
    Table 114. Wet Age Related Macular Degeneration (AMD) Raw Material
    Table 115. Key Suppliers of Wet Age Related Macular Degeneration (AMD) Raw Materials
List of Figures
    Figure 1. Wet Age Related Macular Degeneration (AMD) Picture
    Figure 2. Global Wet Age Related Macular Degeneration (AMD) Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
    Figure 3. Global Wet Age Related Macular Degeneration (AMD) Consumption Value Market Share by Type in 2022
    Figure 4. Wet Age-Related Macular Degeneration (Wet AMD)
    Figure 5. Dry Age-Related Macular Degeneration (Dry AMD)
    Figure 6. Global Wet Age Related Macular Degeneration (AMD) Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
    Figure 7. Wet Age Related Macular Degeneration (AMD) Consumption Value Market Share by Age in 2022
    Figure 8. Above 75 Years Picture
    Figure 9. Above 60 Years Picture
    Figure 10. Above 40 Years Picture
    Figure 11. Global Wet Age Related Macular Degeneration (AMD) Consumption Value, (USD Million): 2018 & 2022 & 2029
    Figure 12. Global Wet Age Related Macular Degeneration (AMD) Consumption Value and Forecast (2018-2029) & (USD Million)
    Figure 13. Global Market Wet Age Related Macular Degeneration (AMD) Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
    Figure 14. Global Wet Age Related Macular Degeneration (AMD) Consumption Value Market Share by Region (2018-2029)
    Figure 15. Global Wet Age Related Macular Degeneration (AMD) Consumption Value Market Share by Region in 2022
    Figure 16. North America Wet Age Related Macular Degeneration (AMD) Consumption Value (2018-2029) & (USD Million)
    Figure 17. Europe Wet Age Related Macular Degeneration (AMD) Consumption Value (2018-2029) & (USD Million)
    Figure 18. Asia-Pacific Wet Age Related Macular Degeneration (AMD) Consumption Value (2018-2029) & (USD Million)
    Figure 19. South America Wet Age Related Macular Degeneration (AMD) Consumption Value (2018-2029) & (USD Million)
    Figure 20. Middle East and Africa Wet Age Related Macular Degeneration (AMD) Consumption Value (2018-2029) & (USD Million)
    Figure 21. Global Wet Age Related Macular Degeneration (AMD) Revenue Share by Players in 2022
    Figure 22. Wet Age Related Macular Degeneration (AMD) Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
    Figure 23. Global Top 3 Players Wet Age Related Macular Degeneration (AMD) Market Share in 2022
    Figure 24. Global Top 6 Players Wet Age Related Macular Degeneration (AMD) Market Share in 2022
    Figure 25. Global Wet Age Related Macular Degeneration (AMD) Consumption Value Share by Type (2018-2023)
    Figure 26. Global Wet Age Related Macular Degeneration (AMD) Market Share Forecast by Type (2024-2029)
    Figure 27. Global Wet Age Related Macular Degeneration (AMD) Consumption Value Share by Age (2018-2023)
    Figure 28. Global Wet Age Related Macular Degeneration (AMD) Market Share Forecast by Age (2024-2029)
    Figure 29. North America Wet Age Related Macular Degeneration (AMD) Consumption Value Market Share by Type (2018-2029)
    Figure 30. North America Wet Age Related Macular Degeneration (AMD) Consumption Value Market Share by Age (2018-2029)
    Figure 31. North America Wet Age Related Macular Degeneration (AMD) Consumption Value Market Share by Country (2018-2029)
    Figure 32. United States Wet Age Related Macular Degeneration (AMD) Consumption Value (2018-2029) & (USD Million)
    Figure 33. Canada Wet Age Related Macular Degeneration (AMD) Consumption Value (2018-2029) & (USD Million)
    Figure 34. Mexico Wet Age Related Macular Degeneration (AMD) Consumption Value (2018-2029) & (USD Million)
    Figure 35. Europe Wet Age Related Macular Degeneration (AMD) Consumption Value Market Share by Type (2018-2029)
    Figure 36. Europe Wet Age Related Macular Degeneration (AMD) Consumption Value Market Share by Age (2018-2029)
    Figure 37. Europe Wet Age Related Macular Degeneration (AMD) Consumption Value Market Share by Country (2018-2029)
    Figure 38. Germany Wet Age Related Macular Degeneration (AMD) Consumption Value (2018-2029) & (USD Million)
    Figure 39. France Wet Age Related Macular Degeneration (AMD) Consumption Value (2018-2029) & (USD Million)
    Figure 40. United Kingdom Wet Age Related Macular Degeneration (AMD) Consumption Value (2018-2029) & (USD Million)
    Figure 41. Russia Wet Age Related Macular Degeneration (AMD) Consumption Value (2018-2029) & (USD Million)
    Figure 42. Italy Wet Age Related Macular Degeneration (AMD) Consumption Value (2018-2029) & (USD Million)
    Figure 43. Asia-Pacific Wet Age Related Macular Degeneration (AMD) Consumption Value Market Share by Type (2018-2029)
    Figure 44. Asia-Pacific Wet Age Related Macular Degeneration (AMD) Consumption Value Market Share by Age (2018-2029)
    Figure 45. Asia-Pacific Wet Age Related Macular Degeneration (AMD) Consumption Value Market Share by Region (2018-2029)
    Figure 46. China Wet Age Related Macular Degeneration (AMD) Consumption Value (2018-2029) & (USD Million)
    Figure 47. Japan Wet Age Related Macular Degeneration (AMD) Consumption Value (2018-2029) & (USD Million)
    Figure 48. South Korea Wet Age Related Macular Degeneration (AMD) Consumption Value (2018-2029) & (USD Million)
    Figure 49. India Wet Age Related Macular Degeneration (AMD) Consumption Value (2018-2029) & (USD Million)
    Figure 50. Southeast Asia Wet Age Related Macular Degeneration (AMD) Consumption Value (2018-2029) & (USD Million)
    Figure 51. Australia Wet Age Related Macular Degeneration (AMD) Consumption Value (2018-2029) & (USD Million)
    Figure 52. South America Wet Age Related Macular Degeneration (AMD) Consumption Value Market Share by Type (2018-2029)
    Figure 53. South America Wet Age Related Macular Degeneration (AMD) Consumption Value Market Share by Age (2018-2029)
    Figure 54. South America Wet Age Related Macular Degeneration (AMD) Consumption Value Market Share by Country (2018-2029)
    Figure 55. Brazil Wet Age Related Macular Degeneration (AMD) Consumption Value (2018-2029) & (USD Million)
    Figure 56. Argentina Wet Age Related Macular Degeneration (AMD) Consumption Value (2018-2029) & (USD Million)
    Figure 57. Middle East and Africa Wet Age Related Macular Degeneration (AMD) Consumption Value Market Share by Type (2018-2029)
    Figure 58. Middle East and Africa Wet Age Related Macular Degeneration (AMD) Consumption Value Market Share by Age (2018-2029)
    Figure 59. Middle East and Africa Wet Age Related Macular Degeneration (AMD) Consumption Value Market Share by Country (2018-2029)
    Figure 60. Turkey Wet Age Related Macular Degeneration (AMD) Consumption Value (2018-2029) & (USD Million)
    Figure 61. Saudi Arabia Wet Age Related Macular Degeneration (AMD) Consumption Value (2018-2029) & (USD Million)
    Figure 62. UAE Wet Age Related Macular Degeneration (AMD) Consumption Value (2018-2029) & (USD Million)
    Figure 63. Wet Age Related Macular Degeneration (AMD) Market Drivers
    Figure 64. Wet Age Related Macular Degeneration (AMD) Market Restraints
    Figure 65. Wet Age Related Macular Degeneration (AMD) Market Trends
    Figure 66. Porters Five Forces Analysis
    Figure 67. Manufacturing Cost Structure Analysis of Wet Age Related Macular Degeneration (AMD) in 2022
    Figure 68. Manufacturing Process Analysis of Wet Age Related Macular Degeneration (AMD)
    Figure 69. Wet Age Related Macular Degeneration (AMD) Industrial Chain
    Figure 70. Methodology
    Figure 71. Research Process and Data Source

Research Methodology

Client Requirements

Review and analyze client requirements

Discussion of all the project requirements and queries

Flexibility Check

Project Feasibility Analysis

Finalizing tentative research programme

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

Determination of key drivers, restraints, challenge, and opportunity

Identifies market needs and trends

Market Size Estimation & Forecast

Estimation of historical data based on secondary and primary data

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

Consideration of geography, region-specific product/service demand for region segments

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

Data Source

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts to verify insights.

Validation and
triangulation of
secondary and primary source.

Collection of data

Cumulating and collating the essential qualitative and quantitative data

Generation of report in client requested format by research analysts

Reviews by expert analysts

Final quality check

Clarifying queries

Receiving feedback

Ensuring satisfaction

01 Identification of data

This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
02 Evaluation of Market Dynamic

This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
03 Collection of Data

This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
04 Collaboration of Data

This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis

This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

Companies Mentioned

Novartis International (Switzerland)
Bayer (Germany)
Acucela (US)
Neurotech Pharmaceuticals (US)
Ophthotech (US)
GlaxoSmithKline (US)
Alimera Sciences (US)
StemCell (Canada)
F. Hoffmann-La Roche (Switzerland)
Regeneron Pharmaceutical (US)
Allergan (Ireland)
Adverum Biotechnologies (US)
Gilead Sciences (US)

Related Reports

Global Wet Age Related Macular Degeneration (AMD) Supply, Demand and Key Producers, 2023-2029

Global Wet Age Related Macular Degeneration (AMD) Supply, Demand and Key Producers, 2023-2029

date 06 Feb 2023

date Medical Care

Increased disease burden due to rising geriatric population is one of the major factors driving the growth of the global age-related macular degeneration (AMD) market. This market is expected to surpass a valuation of USD 2,200 Mn by the end of 2023. AMD remains a major cause of central visual loss, effecting close to 10% of people older than 65 years and over 25% of people older than 75 years globally.

Global Wet Age Related Macular Degeneration (AMD) Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Global Wet Age Related Macular Degeneration (AMD) Market 2024 by Company, Regions, Type and Application, Forecast to 2030

date 02 Jan 2024

date Medical Care

According to our (Global Info Research) latest study, the global Wet Age Related Macular Degeneration (AMD) market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.

Product Tags

Organ Rejection Prophylaxis Treatment

Biologics Analytical Services

Purchase Options

Single User License

USD3480.00

Multi User License

USD5220.00

Corporate Users License

USD6960.00

Add To Cart

Buy Now

Popular Product Keywords

AI
semiconductor
electron
5G
artificial intelligence
Battery
new energy
We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.

Speak to our analyst >>
Our Clients
What We Can Provide?

With better results and higher quality products,Our professional reports can achieve four things:
- Insight into the industry market information
- Analyze market development needs
- Prospects for future development
- Develop industry investment strategy
Digging deeper into global industry information and providing market strategies.

Contact Us >>